Crum R M, Galai N, Cohn S, Celentano D D, Vlahov D
Department of Epidemiology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland, USA.
Alcohol Clin Exp Res. 1996 Apr;20(2):364-71. doi: 10.1111/j.1530-0277.1996.tb01654.x.
Alcohol use is known to alter immune function and has immunosuppressive effects that may modify T-lymphocyte subpopulations. However, there is no clear evidence regarding the relationship of alcohol use with the progression of immunodeficiency in human immunodeficiency virus-type 1 (HIV-1)-seropositive individuals, particularly injection drug users (IDUs).
Using prospective data from a cohort of IDUs in a study of the natural history of HIV infection, we examined the relationship of alcohol use and changes in T-lymphocyte subsets. Among the 2921 IDUs followed semiannually in outpatient clinics, 188 were documented HIV-1 seroconverters with known time of seroconversion. At each visit, all study participants were interviewed, underwent physical examinations, and had blood drawn for laboratory studies. Alcohol use was measured by reported frequency and quantity of alcoholic beverages. Longitudinal analyses included data for up to 5 years postseroconversion. To formally test the association of alcohol use with change in levels of CD4+ and CD8+ cells subsequent to HIV seroconversion, regression models incorporating autocorrelation structure were applied.
Alcohol use was not appreciably related to age, gender, marital status, income, education, or the duration of intravenous drug use. CD4% decreased for all IDUs within the first 5 years after seroconversion, with no significant differences between alcohol categories. CD8% increased for all IDUs, with no significant differences by alcohol category within the first 2 years after seroconversion. However, between 2 to 5 years postseroconversion, there was a statistically significant increase among the heaviest drinkers: CD8% increased 6.9%/year [95% confidence interval (CI): 4.7, 8.0] for the IDUs who reported > 21 drinks/week, 2.4%/year (95% CI: 0.8, 4.0) for IDUs who drank 21 drinks/week or less, and 0.4% (95% CI: -2.1, 2.9) for abstainers. Similar results were obtained for CD4 and CD8 absolute counts.
In this study population of IDUs, CD8% (but not CD4%) is associated with alcohol consumption early after HIV seroconversion. This is the first prospective study to date to assess the relationship of alcohol use with HIV progression from the time of HIV seroconversion among a cohort of IDUs. If confirmed in future investigations, the findings may have significant implications for prevention and early intervention programs aimed at inhibiting disease progression among HIV-positive IDUs.
已知饮酒会改变免疫功能并具有免疫抑制作用,可能会改变T淋巴细胞亚群。然而,关于饮酒与1型人类免疫缺陷病毒(HIV-1)血清阳性个体,特别是注射吸毒者(IDU)免疫缺陷进展之间的关系,尚无明确证据。
利用一项关于HIV感染自然史研究中IDU队列的前瞻性数据,我们研究了饮酒与T淋巴细胞亚群变化之间的关系。在2921名每半年在门诊随访的IDU中,188名是记录了血清转化时间的HIV-1血清转化者。每次随访时,所有研究参与者都接受访谈、体格检查,并抽取血液进行实验室研究。饮酒情况通过报告的酒精饮料饮用频率和数量来衡量。纵向分析包括血清转化后长达5年的数据。为了正式检验饮酒与HIV血清转化后CD4+和CD8+细胞水平变化之间的关联,应用了纳入自相关结构的回归模型。
饮酒与年龄、性别、婚姻状况、收入、教育程度或静脉吸毒持续时间没有明显关系。所有IDU在血清转化后的前5年内CD4%均下降,不同饮酒类别之间无显著差异。所有IDU的CD8%均升高,在血清转化后的前2年内不同饮酒类别之间无显著差异。然而,在血清转化后2至5年期间,饮酒量最大者有统计学显著升高:报告每周饮酒超过21杯的IDU,其CD8%每年升高6.9%[95%置信区间(CI):4.7, 8.0];每周饮酒21杯及以下的IDU,其CD8%每年升高2.4%(95%CI:0.8, 4.0);戒酒者的CD8%升高0.4%(95%CI:-2.1, 2.9)。CD4和CD8绝对计数也得到了类似结果。
在该IDU研究人群中,HIV血清转化后早期,CD8%(而非CD4%)与饮酒量有关。这是迄今为止第一项评估IDU队列中从HIV血清转化时起饮酒与HIV进展关系的前瞻性研究。如果在未来研究中得到证实,这些发现可能对旨在抑制HIV阳性IDU疾病进展的预防和早期干预项目具有重要意义。